Real-time Estimate
Cboe BZX
09:52:32 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
3.425
USD
|
+1.03%
|
|
+5.47%
|
-31.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,720
|
8,087
|
3,960
|
1,093
|
709.4
|
499.6
|
-
|
-
|
Enterprise Value (EV)
1 |
3,720
|
7,399
|
3,607
|
594.4
|
653.7
|
484.7
|
491.7
|
574.7
|
P/E ratio
|
-29.6
x
|
-53.3
x
|
-19
x
|
-5.46
x
|
-3.14
x
|
-2.64
x
|
-3.23
x
|
-4.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
43.7
x
|
82.2
x
|
25.7
x
|
5.9
x
|
4.17
x
|
2.96
x
|
2.42
x
|
1.87
x
|
EV / Revenue
|
43.7
x
|
75.2
x
|
23.4
x
|
3.21
x
|
3.84
x
|
2.87
x
|
2.38
x
|
2.15
x
|
EV / EBITDA
|
-64.7
x
|
-61.9
x
|
-23.8
x
|
-4.89
x
|
-5.62
x
|
-4.57
x
|
-8.3
x
|
-18.4
x
|
EV / FCF
|
19.2
x
|
-43.9
x
|
-14.2
x
|
-2.97
x
|
-3.91
x
|
-4.85
x
|
-11.4
x
|
-47.9
x
|
FCF Yield
|
5.22%
|
-2.28%
|
-7.05%
|
-33.7%
|
-25.5%
|
-20.6%
|
-8.75%
|
-2.09%
|
Price to Book
|
3.62
x
|
10.4
x
|
6.57
x
|
2.36
x
|
2.29
x
|
3.32
x
|
5.15
x
|
14.8
x
|
Nbr of stocks (in thousands)
|
124,339
|
136,772
|
141,132
|
143,012
|
144,773
|
147,368
|
-
|
-
|
Reference price
2 |
29.92
|
59.13
|
28.06
|
7.640
|
4.900
|
3.390
|
3.390
|
3.390
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/15/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
85.07
|
98.38
|
154.3
|
185.3
|
170.3
|
168.7
|
206.7
|
267.3
|
EBITDA
1 |
-57.48
|
-119.6
|
-151.7
|
-121.6
|
-116.4
|
-106
|
-59.25
|
-31.19
|
EBIT
1 |
-78.39
|
-152.8
|
-209
|
-200.2
|
-227
|
-179.9
|
-139.4
|
-113.1
|
Operating Margin
|
-92.15%
|
-155.33%
|
-135.39%
|
-108.03%
|
-133.33%
|
-106.64%
|
-67.42%
|
-42.32%
|
Earnings before Tax (EBT)
1 |
-68.61
|
-146.2
|
-207.3
|
-200.4
|
-225.3
|
-188.6
|
-147.9
|
-127.3
|
Net income
1 |
-69.57
|
-146.2
|
-207.3
|
-200.2
|
-225.2
|
-188.6
|
-148
|
-127.2
|
Net margin
|
-81.78%
|
-148.63%
|
-134.3%
|
-108.03%
|
-132.29%
|
-111.83%
|
-71.57%
|
-47.59%
|
EPS
2 |
-1.010
|
-1.110
|
-1.480
|
-1.400
|
-1.560
|
-1.285
|
-1.051
|
-0.8429
|
Free Cash Flow
1 |
194.2
|
-168.5
|
-254.5
|
-200.3
|
-167
|
-100
|
-43
|
-12
|
FCF margin
|
228.28%
|
-171.26%
|
-164.87%
|
-108.09%
|
-98.09%
|
-59.29%
|
-20.8%
|
-4.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/15/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
37.93
|
38.62
|
43.66
|
47.83
|
55.2
|
37.65
|
48.93
|
37.92
|
45.78
|
41.87
|
39.39
|
40.38
|
46.67
|
45.9
|
49.62
|
EBITDA
1 |
-44.95
|
-45.15
|
-33.13
|
-25.87
|
-19.56
|
-37.1
|
-24.82
|
-29.83
|
-24.66
|
-28.18
|
-24.37
|
-24.54
|
-24.9
|
-18.88
|
-14.97
|
EBIT
1 |
-61.6
|
-63.07
|
-52.5
|
-45.43
|
-39.19
|
-57.19
|
-47.82
|
-50.96
|
-71.07
|
-47.72
|
-45.23
|
-44.29
|
-42.85
|
-41.52
|
-40.25
|
Operating Margin
|
-162.39%
|
-163.3%
|
-120.25%
|
-94.98%
|
-70.99%
|
-151.92%
|
-97.74%
|
-134.38%
|
-155.22%
|
-113.96%
|
-114.83%
|
-109.68%
|
-91.8%
|
-90.46%
|
-81.1%
|
Earnings before Tax (EBT)
1 |
-61.36
|
-62.8
|
-52.08
|
-45.32
|
-40.17
|
-57.7
|
-47.81
|
-50.33
|
-69.47
|
-47.53
|
-46.37
|
-46.8
|
-46.55
|
-41.92
|
-40.88
|
Net income
1 |
-61.43
|
-62.74
|
-52.05
|
-45.28
|
-40.13
|
-57.7
|
-47.81
|
-50.3
|
-69.44
|
-47.51
|
-46.37
|
-46.8
|
-46.55
|
-41.92
|
-40.88
|
Net margin
|
-161.96%
|
-162.44%
|
-119.21%
|
-94.67%
|
-72.7%
|
-153.26%
|
-97.72%
|
-132.65%
|
-151.67%
|
-113.45%
|
-117.73%
|
-115.89%
|
-99.73%
|
-91.33%
|
-82.37%
|
EPS
2 |
-0.4300
|
-0.4400
|
-0.3700
|
-0.3200
|
-0.2800
|
-0.4000
|
-0.3300
|
-0.3500
|
-0.4800
|
-0.3300
|
-0.3154
|
-0.3178
|
-0.3170
|
-0.2833
|
-0.2733
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/15/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/14/23
|
5/3/23
|
8/2/23
|
11/9/23
|
2/14/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
75.2
|
Net Cash position
1 |
-
|
688
|
353
|
498
|
55.7
|
14.9
|
7.88
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2.41
x
|
Free Cash Flow
1 |
194
|
-168
|
-254
|
-200
|
-167
|
-100
|
-43
|
-12
|
ROE (net income / shareholders' equity)
|
-44.5%
|
-22.3%
|
-30.8%
|
-37.5%
|
-51.7%
|
-83.1%
|
-107%
|
-150%
|
ROA (Net income/ Total Assets)
|
-11.2%
|
-14.4%
|
-20.3%
|
-22.5%
|
-26.3%
|
-33.2%
|
-26.9%
|
-24.3%
|
Assets
1 |
622.3
|
1,014
|
1,020
|
890
|
855.4
|
568.8
|
549.8
|
523.4
|
Book Value Per Share
2 |
8.260
|
5.660
|
4.270
|
3.240
|
2.140
|
1.020
|
0.6600
|
0.2300
|
Cash Flow per Share
|
2.970
|
-1.140
|
-1.370
|
-1.290
|
-
|
-
|
-
|
-
|
Capex
1 |
11.2
|
18.8
|
61.7
|
16.3
|
10.7
|
12
|
16
|
19
|
Capex / Sales
|
13.17%
|
19.11%
|
40.01%
|
8.82%
|
6.28%
|
7.11%
|
7.74%
|
7.11%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/15/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
3.39
USD Average target price
6.333
USD Spread / Average Target +86.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -31.12% | 500M | | -40.65% | 7.63B | | +7.99% | 3.61B | | +3.26% | 2.36B | | -24.94% | 1.86B | | -17.67% | 1.74B | | +3.05% | 913M | | +19.71% | 763M | | -11.57% | 678M | | +4.37% | 290M |
Bio Diagnostics & Testing
|